Skip to main content
. 2023 Dec 14;23:118. doi: 10.1186/s40644-023-00629-9

Table 1.

Baseline characteristics of patients in the training and validation cohorts

Characteristic Training cohort
(n = 169)
Validation cohort
(n = 111)
P-value
Recurrence 0.941
Absence 115 (68.0) 76 (68.5)
Presence 54 (32.0) 35 (31.5)
Clinicopathologic features
Age (years)a 40.25 ± 13.71 41.47 ± 13.49 0.466
Sex 0.479
Male 54 (32.0) 40 (36.0)
female 115 (68.0) 71 (64.0)
Tumor size (mm)a 20.36 ± 10.20 22.31 ± 11.85 0.156
Bilaterality 0.572
Absence 85 (50.3) 52 (46.8)
Presence 84 (49.7) 59 (53.2)
Multifocality 0.383
Absence 65 (38.5) 37 (33.3)
Presence 104 (61.5) 74 (66.7)
Extrathyroidal extension 0.161
Absence 13 (7.7) 4 (3.6)
Presence 156 (92.3) 107 (96.4)
Number of metastatic LNb 11 (5–19) 10 (4–19) 0.874
Concomitant thyroid disease 0.107
Neither 43 (25.4) 30 (27.0)
Nodular goiter 80 (47.3) 62 (55.9)
Hashimoto’s thyroiditis 41 (24.3) 14 (12.6)
Both 5 (3.0) 5 (4.5)
Surgical option 0.302
Total thyroidectomy 140 (82.8) 97 (87.4)
Subtotal or semi-total thyroidectomy 29 (17.2) 14 (12.6)
T stage 0.697
T1a 3 (1.8) 0 (0)
T1b 6 (3.6) 3 (2.7)
T2 2 (1.2) 1 (0.9)
T3 137 (81.1) 96 (86.5)
T4a 21 (12.4) 11 (9.9)
N stage 0.897
N0 17 (10.1) 10 (9.0)
N1a 23 (13.6) 17 (15.3)
N1b 129 (76.3) 84 (75.7)
131I radiotherapy 0.359
Not received 88 (52.1) 64 (57.7)
Received 81 (47.9) 47 (42.3)
Family history 0.385
Absence 159 (94.1) 107 (96.4)
Presence 10 (5.9) 4 (3.6)
CT features
Shape 0.594
Regular 30 (17.8) 17 (15.3)
Irregular 139 (82.2) 94 (84.7)
Margin 0.588
Well-defined 24 (14.2) 19 (17.1)
Ill-defined 145 (85.8) 92 (82.9)
Calcification 0.172
Absence 81 (47.9) 44 (39.6)
Presence 88 (52.1) 67 (60.4)
CT-reported LN status 0.291
Negative 35 (20.7) 29 (26.1)
Positive 134 (79.3) 82 (73.9)

Unless otherwise indicated, data are the number of patients and data in parentheses are percentages

a Data are means ± standard deviation

b Data are medians, with interquartile range in parentheses

CT: computed tomography; LN: lymph nodes